Ionis: FDA Accepts For Priority Review NDA For Zilganersen

FDA has accepted Ionis Pharmaceuticals' NDA for zilganersen for Priority Review and set a PDUFA target action date of September 22, 2026. The filing covers an investigational RNA-targeted therapy for Alexander disease. Priority Review is an expedited regulatory pathway and represents a positive near-term catalyst for Ionis, though approval is not guaranteed.

Analysis

FDA has accepted Ionis Pharmaceuticals' NDA for zilganersen for Priority Review and set a PDUFA target action date of September 22, 2026. The filing covers an investigational RNA-targeted therapy for Alexander disease. Priority Review is an expedited regulatory pathway and represents a positive near-term catalyst for Ionis, though approval is not guaranteed.